| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 43 | 2025 | 957 | 4.070 |
Why?
|
| AIDS-Related Opportunistic Infections | 20 | 2013 | 67 | 2.380 |
Why?
|
| Anti-HIV Agents | 15 | 2018 | 139 | 1.950 |
Why?
|
| Acquired Immunodeficiency Syndrome | 11 | 2010 | 129 | 1.670 |
Why?
|
| Antiretroviral Therapy, Highly Active | 15 | 2013 | 94 | 1.300 |
Why?
|
| Staphylococcus aureus | 6 | 2008 | 181 | 1.220 |
Why?
|
| CD4 Lymphocyte Count | 22 | 2020 | 92 | 1.170 |
Why?
|
| Methicillin Resistance | 6 | 2008 | 23 | 1.170 |
Why?
|
| Anti-Bacterial Agents | 11 | 2017 | 806 | 0.970 |
Why?
|
| HIV-1 | 15 | 2022 | 706 | 0.920 |
Why?
|
| Community-Acquired Infections | 6 | 2017 | 95 | 0.890 |
Why?
|
| Viral Load | 16 | 2021 | 230 | 0.830 |
Why?
|
| Cytomegalovirus Retinitis | 5 | 2002 | 6 | 0.830 |
Why?
|
| Staphylococcal Infections | 6 | 2008 | 131 | 0.660 |
Why?
|
| Encephalitis, Tick-Borne | 1 | 2019 | 5 | 0.610 |
Why?
|
| Encephalitis Viruses, Tick-Borne | 1 | 2019 | 6 | 0.610 |
Why?
|
| Adult | 53 | 2025 | 17461 | 0.600 |
Why?
|
| HIV Protease Inhibitors | 5 | 2011 | 110 | 0.590 |
Why?
|
| Toxoplasmosis, Cerebral | 3 | 2013 | 6 | 0.580 |
Why?
|
| Staphylococcal Skin Infections | 3 | 2007 | 12 | 0.580 |
Why?
|
| Humans | 98 | 2025 | 65463 | 0.550 |
Why?
|
| Male | 63 | 2025 | 31187 | 0.550 |
Why?
|
| Encephalitis | 3 | 2013 | 37 | 0.540 |
Why?
|
| Neuroimaging | 1 | 2019 | 165 | 0.530 |
Why?
|
| Middle Aged | 43 | 2025 | 18387 | 0.530 |
Why?
|
| Reverse Transcriptase Inhibitors | 4 | 2010 | 28 | 0.500 |
Why?
|
| Female | 57 | 2025 | 34193 | 0.470 |
Why?
|
| HIV Seropositivity | 2 | 2015 | 81 | 0.440 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2010 | 206 | 0.430 |
Why?
|
| Candidiasis | 4 | 2007 | 49 | 0.430 |
Why?
|
| Triazoles | 4 | 2007 | 63 | 0.430 |
Why?
|
| Catheterization, Central Venous | 3 | 2000 | 84 | 0.410 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2020 | 2250 | 0.390 |
Why?
|
| Pneumonia, Bacterial | 5 | 2017 | 91 | 0.390 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 2 | 2013 | 17 | 0.380 |
Why?
|
| Brain | 3 | 2019 | 1611 | 0.380 |
Why?
|
| RNA, Viral | 6 | 2022 | 266 | 0.350 |
Why?
|
| Drug Resistance, Viral | 2 | 2010 | 160 | 0.350 |
Why?
|
| Influenza, Human | 3 | 2003 | 209 | 0.340 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2011 | 3 | 0.340 |
Why?
|
| Pyrrolidinones | 1 | 2011 | 11 | 0.340 |
Why?
|
| Osteonecrosis | 2 | 2001 | 6 | 0.340 |
Why?
|
| Breast Diseases | 1 | 2011 | 45 | 0.330 |
Why?
|
| Naltrexone | 3 | 2018 | 91 | 0.330 |
Why?
|
| HIV | 4 | 2014 | 67 | 0.320 |
Why?
|
| Methicillin | 2 | 2008 | 5 | 0.320 |
Why?
|
| Severity of Illness Index | 4 | 2014 | 1564 | 0.320 |
Why?
|
| Comorbidity | 3 | 2011 | 1120 | 0.320 |
Why?
|
| Narcotic Antagonists | 3 | 2018 | 133 | 0.310 |
Why?
|
| Anti-Retroviral Agents | 5 | 2020 | 76 | 0.310 |
Why?
|
| Respiration, Artificial | 4 | 2021 | 298 | 0.310 |
Why?
|
| Anti-Infective Agents | 3 | 2002 | 152 | 0.310 |
Why?
|
| Organophosphonates | 2 | 2000 | 22 | 0.300 |
Why?
|
| Withholding Treatment | 4 | 2018 | 38 | 0.300 |
Why?
|
| Lymphadenitis | 2 | 2007 | 5 | 0.300 |
Why?
|
| Risk Factors | 13 | 2017 | 5458 | 0.300 |
Why?
|
| Bacteremia | 4 | 2000 | 91 | 0.300 |
Why?
|
| Drug Administration Schedule | 9 | 2018 | 296 | 0.300 |
Why?
|
| Soft Tissue Infections | 2 | 2006 | 48 | 0.290 |
Why?
|
| Warts | 1 | 2008 | 7 | 0.290 |
Why?
|
| Health Care Costs | 3 | 2010 | 224 | 0.280 |
Why?
|
| Antifungal Agents | 5 | 2007 | 125 | 0.280 |
Why?
|
| Nose | 1 | 2008 | 27 | 0.280 |
Why?
|
| Antiviral Agents | 3 | 2000 | 326 | 0.270 |
Why?
|
| Body Composition | 1 | 2008 | 155 | 0.270 |
Why?
|
| Hospitalization | 6 | 2021 | 1399 | 0.260 |
Why?
|
| Prospective Studies | 11 | 2018 | 3324 | 0.260 |
Why?
|
| Retrospective Studies | 20 | 2017 | 6929 | 0.260 |
Why?
|
| Aspergillosis | 1 | 2007 | 35 | 0.260 |
Why?
|
| Enteral Nutrition | 2 | 1997 | 53 | 0.250 |
Why?
|
| Cross Infection | 4 | 2017 | 170 | 0.250 |
Why?
|
| Stomach | 2 | 1997 | 87 | 0.250 |
Why?
|
| Daptomycin | 1 | 2006 | 9 | 0.240 |
Why?
|
| Lipids | 1 | 2008 | 328 | 0.240 |
Why?
|
| Aged | 23 | 2021 | 15052 | 0.230 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2005 | 14 | 0.230 |
Why?
|
| Ganciclovir | 3 | 2000 | 18 | 0.230 |
Why?
|
| Prisoners | 3 | 2018 | 179 | 0.230 |
Why?
|
| Quinolines | 1 | 2025 | 47 | 0.220 |
Why?
|
| Cryptococcus neoformans | 1 | 2005 | 142 | 0.210 |
Why?
|
| Opioid-Related Disorders | 3 | 2018 | 529 | 0.210 |
Why?
|
| Guideline Adherence | 2 | 2017 | 310 | 0.200 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2003 | 8 | 0.200 |
Why?
|
| Survival Analysis | 7 | 2015 | 578 | 0.200 |
Why?
|
| Viral Matrix Proteins | 1 | 2003 | 50 | 0.200 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2025 | 214 | 0.200 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2003 | 39 | 0.190 |
Why?
|
| Cytomegalovirus Infections | 1 | 2003 | 68 | 0.190 |
Why?
|
| Antigens, Viral | 1 | 2003 | 130 | 0.190 |
Why?
|
| Benzoxazines | 3 | 2015 | 11 | 0.190 |
Why?
|
| Cytomegalovirus | 1 | 2003 | 94 | 0.190 |
Why?
|
| Esophageal Diseases | 3 | 2007 | 16 | 0.190 |
Why?
|
| Mutation | 2 | 2010 | 2666 | 0.190 |
Why?
|
| Vaccination | 2 | 2003 | 384 | 0.180 |
Why?
|
| Drug Hypersensitivity | 2 | 2003 | 28 | 0.180 |
Why?
|
| Phosphoproteins | 1 | 2003 | 224 | 0.180 |
Why?
|
| Fluconazole | 3 | 2007 | 11 | 0.180 |
Why?
|
| Focal Infection | 1 | 2002 | 1 | 0.180 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 2 | 1999 | 8 | 0.180 |
Why?
|
| Oxazolidinones | 1 | 2002 | 16 | 0.180 |
Why?
|
| Pneumonia | 2 | 2016 | 295 | 0.180 |
Why?
|
| Influenza Vaccines | 1 | 2003 | 98 | 0.180 |
Why?
|
| Acetamides | 1 | 2002 | 17 | 0.180 |
Why?
|
| Treatment Failure | 4 | 2021 | 208 | 0.180 |
Why?
|
| Vision Disorders | 1 | 2002 | 69 | 0.180 |
Why?
|
| Listeria monocytogenes | 2 | 2012 | 33 | 0.170 |
Why?
|
| Immunoglobulin G | 3 | 2014 | 466 | 0.170 |
Why?
|
| Proviruses | 2 | 2018 | 27 | 0.170 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 1998 | 41 | 0.170 |
Why?
|
| Incidence | 5 | 2007 | 1430 | 0.170 |
Why?
|
| Quality of Life | 1 | 2008 | 1263 | 0.170 |
Why?
|
| Texas | 3 | 2006 | 60 | 0.170 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2021 | 15 | 0.170 |
Why?
|
| Thrombocytopenia | 1 | 2002 | 59 | 0.170 |
Why?
|
| Drug Therapy, Combination | 6 | 2011 | 463 | 0.160 |
Why?
|
| Treatment Outcome | 14 | 2018 | 5806 | 0.160 |
Why?
|
| Protease Inhibitors | 1 | 2001 | 106 | 0.160 |
Why?
|
| Fatal Outcome | 2 | 2013 | 122 | 0.160 |
Why?
|
| Thallium | 1 | 2000 | 2 | 0.160 |
Why?
|
| Cohort Studies | 9 | 2015 | 2633 | 0.160 |
Why?
|
| Anemia | 1 | 2002 | 132 | 0.160 |
Why?
|
| Nervous System Diseases | 1 | 2002 | 108 | 0.160 |
Why?
|
| Drugs, Investigational | 1 | 2000 | 12 | 0.160 |
Why?
|
| Guanine | 1 | 2000 | 26 | 0.160 |
Why?
|
| Sulfamethoxazole | 2 | 2007 | 5 | 0.150 |
Why?
|
| Catheterization, Peripheral | 1 | 2000 | 51 | 0.150 |
Why?
|
| Adenine | 1 | 2000 | 48 | 0.150 |
Why?
|
| Transcriptome | 1 | 2022 | 399 | 0.150 |
Why?
|
| Time Factors | 7 | 2018 | 3774 | 0.150 |
Why?
|
| HIV Long-Term Survivors | 1 | 2018 | 8 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 252 | 0.140 |
Why?
|
| Bacterial Toxins | 3 | 2011 | 58 | 0.140 |
Why?
|
| Cardiomyopathies | 1 | 2020 | 137 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 676 | 0.140 |
Why?
|
| Virus Integration | 1 | 2018 | 33 | 0.140 |
Why?
|
| Toxoplasma | 2 | 2013 | 34 | 0.140 |
Why?
|
| Haptens | 1 | 1998 | 14 | 0.140 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2000 | 204 | 0.140 |
Why?
|
| Genotype | 2 | 2010 | 674 | 0.140 |
Why?
|
| Enterococcus faecalis | 1 | 1998 | 11 | 0.130 |
Why?
|
| Mycobacterium | 1 | 1998 | 37 | 0.130 |
Why?
|
| Adolescent | 6 | 2014 | 6332 | 0.130 |
Why?
|
| Aging | 1 | 2003 | 774 | 0.130 |
Why?
|
| DNA, Viral | 1 | 2018 | 232 | 0.130 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 1997 | 22 | 0.130 |
Why?
|
| Case-Control Studies | 5 | 2003 | 1143 | 0.130 |
Why?
|
| Eosinophilia | 1 | 1997 | 37 | 0.130 |
Why?
|
| Respiratory System | 1 | 1997 | 46 | 0.130 |
Why?
|
| Exotoxins | 2 | 2006 | 7 | 0.120 |
Why?
|
| Leukocidins | 2 | 2006 | 7 | 0.120 |
Why?
|
| Brain Neoplasms | 1 | 2000 | 319 | 0.120 |
Why?
|
| Agranulocytosis | 2 | 1994 | 6 | 0.120 |
Why?
|
| Liver Function Tests | 2 | 2014 | 38 | 0.120 |
Why?
|
| Follow-Up Studies | 5 | 2018 | 2492 | 0.120 |
Why?
|
| Hospital Mortality | 3 | 2021 | 879 | 0.120 |
Why?
|
| Fluoroquinolones | 1 | 2016 | 33 | 0.120 |
Why?
|
| Viremia | 3 | 2023 | 46 | 0.120 |
Why?
|
| Dental Care for Chronically Ill | 1 | 1995 | 4 | 0.110 |
Why?
|
| Erythromycin | 1 | 1995 | 4 | 0.110 |
Why?
|
| Listeriosis | 2 | 2012 | 29 | 0.110 |
Why?
|
| Hip Prosthesis | 1 | 1995 | 24 | 0.110 |
Why?
|
| Family Practice | 1 | 1997 | 215 | 0.110 |
Why?
|
| Prosthesis-Related Infections | 1 | 1995 | 34 | 0.110 |
Why?
|
| Pneumococcal Vaccines | 1 | 2014 | 22 | 0.110 |
Why?
|
| Prognosis | 1 | 2019 | 1789 | 0.110 |
Why?
|
| Bacteroides fragilis | 1 | 1994 | 5 | 0.110 |
Why?
|
| Pericarditis | 1 | 1994 | 10 | 0.110 |
Why?
|
| Pneumococcal Infections | 1 | 2014 | 39 | 0.110 |
Why?
|
| Streptococcal Infections | 1 | 1995 | 85 | 0.110 |
Why?
|
| Prevalence | 3 | 2010 | 1451 | 0.100 |
Why?
|
| Hospital Information Systems | 1 | 2014 | 10 | 0.100 |
Why?
|
| Young Adult | 4 | 2014 | 4837 | 0.100 |
Why?
|
| Double-Blind Method | 4 | 2021 | 743 | 0.100 |
Why?
|
| Herpes Simplex | 1 | 1994 | 49 | 0.100 |
Why?
|
| Diagnosis, Differential | 5 | 2003 | 990 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 2 | 2012 | 414 | 0.100 |
Why?
|
| Appendicitis | 1 | 1994 | 84 | 0.100 |
Why?
|
| Drug Utilization | 1 | 2015 | 204 | 0.100 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2010 | 704 | 0.100 |
Why?
|
| Safety | 2 | 2004 | 142 | 0.100 |
Why?
|
| Patient Selection | 2 | 2007 | 484 | 0.100 |
Why?
|
| Cell Cycle Proteins | 2 | 2007 | 403 | 0.100 |
Why?
|
| Biopsy | 2 | 2013 | 460 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2018 | 247 | 0.100 |
Why?
|
| Heart | 2 | 2012 | 298 | 0.100 |
Why?
|
| Hepatitis B Antibodies | 1 | 2012 | 9 | 0.100 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2012 | 18 | 0.100 |
Why?
|
| Candidiasis, Oral | 3 | 2007 | 6 | 0.090 |
Why?
|
| Hepatitis B Vaccines | 1 | 2012 | 16 | 0.090 |
Why?
|
| Living Donors | 1 | 2012 | 78 | 0.090 |
Why?
|
| Adipose Tissue | 2 | 2020 | 300 | 0.090 |
Why?
|
| Length of Stay | 4 | 2017 | 828 | 0.090 |
Why?
|
| Genome, Bacterial | 1 | 2012 | 67 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1997 | 769 | 0.090 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 105 | 0.090 |
Why?
|
| Abscess | 1 | 2012 | 79 | 0.090 |
Why?
|
| Immunocompromised Host | 2 | 2007 | 103 | 0.090 |
Why?
|
| Gynecomastia | 1 | 2011 | 11 | 0.090 |
Why?
|
| Raltegravir Potassium | 1 | 2011 | 1 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2018 | 931 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2016 | 371 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 734 | 0.080 |
Why?
|
| Serologic Tests | 2 | 2021 | 34 | 0.080 |
Why?
|
| Delayed-Action Preparations | 3 | 2018 | 120 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2011 | 105 | 0.080 |
Why?
|
| Acute Disease | 3 | 2010 | 663 | 0.080 |
Why?
|
| Alcoholism | 1 | 2014 | 329 | 0.080 |
Why?
|
| Models, Biological | 2 | 2014 | 1192 | 0.080 |
Why?
|
| Drug Resistance, Fungal | 2 | 2007 | 10 | 0.080 |
Why?
|
| AIDS Dementia Complex | 1 | 2010 | 11 | 0.080 |
Why?
|
| Pharyngeal Diseases | 2 | 2007 | 11 | 0.080 |
Why?
|
| Quinolones | 1 | 2010 | 25 | 0.080 |
Why?
|
| Macrolides | 1 | 2010 | 38 | 0.080 |
Why?
|
| Kidney Transplantation | 1 | 2012 | 325 | 0.080 |
Why?
|
| Foscarnet | 2 | 2000 | 2 | 0.080 |
Why?
|
| Probability | 2 | 2007 | 170 | 0.080 |
Why?
|
| Histone Acetyltransferases | 2 | 2007 | 59 | 0.080 |
Why?
|
| Cytosine | 2 | 2000 | 31 | 0.080 |
Why?
|
| Organophosphorus Compounds | 2 | 2000 | 33 | 0.070 |
Why?
|
| Amino Acid Substitution | 1 | 2010 | 238 | 0.070 |
Why?
|
| Recurrence | 2 | 2008 | 662 | 0.070 |
Why?
|
| Paralysis | 1 | 2009 | 17 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2010 | 190 | 0.070 |
Why?
|
| Triglycerides | 2 | 2020 | 248 | 0.070 |
Why?
|
| Gene Products, tat | 2 | 2007 | 14 | 0.070 |
Why?
|
| Choriocarcinoma | 1 | 2008 | 3 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2010 | 224 | 0.070 |
Why?
|
| Disease Progression | 2 | 2007 | 1223 | 0.070 |
Why?
|
| ras Proteins | 1 | 2008 | 76 | 0.070 |
Why?
|
| Virus Replication | 2 | 2007 | 323 | 0.070 |
Why?
|
| Uterine Neoplasms | 1 | 2008 | 36 | 0.070 |
Why?
|
| Viral Proteins | 1 | 2010 | 270 | 0.070 |
Why?
|
| Transcription Factors | 2 | 2007 | 1557 | 0.070 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1988 | 59 | 0.070 |
Why?
|
| Immunoglobulin M | 1 | 1988 | 116 | 0.070 |
Why?
|
| Terminology as Topic | 1 | 2008 | 144 | 0.070 |
Why?
|
| Voriconazole | 1 | 2007 | 5 | 0.070 |
Why?
|
| Molecular Sequence Data | 4 | 2012 | 1979 | 0.070 |
Why?
|
| Hospital Costs | 2 | 2015 | 126 | 0.070 |
Why?
|
| Empirical Research | 1 | 2007 | 15 | 0.070 |
Why?
|
| Cellulitis | 1 | 2007 | 16 | 0.060 |
Why?
|
| Splenomegaly | 1 | 2007 | 22 | 0.060 |
Why?
|
| HIV Long Terminal Repeat | 1 | 2007 | 11 | 0.060 |
Why?
|
| Cytoskeleton | 1 | 1988 | 141 | 0.060 |
Why?
|
| Neck | 1 | 2007 | 46 | 0.060 |
Why?
|
| RecQ Helicases | 1 | 2007 | 9 | 0.060 |
Why?
|
| Positive Transcriptional Elongation Factor B | 1 | 2007 | 9 | 0.060 |
Why?
|
| Itraconazole | 1 | 2007 | 14 | 0.060 |
Why?
|
| Hospitals, County | 1 | 2006 | 2 | 0.060 |
Why?
|
| Stomatitis, Aphthous | 1 | 2006 | 2 | 0.060 |
Why?
|
| Oral Ulcer | 1 | 2006 | 3 | 0.060 |
Why?
|
| Retroviridae | 1 | 2007 | 75 | 0.060 |
Why?
|
| Skin | 2 | 2008 | 428 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2016 | 5644 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2007 | 144 | 0.060 |
Why?
|
| Injections, Intramuscular | 2 | 2018 | 71 | 0.060 |
Why?
|
| Confidence Intervals | 1 | 2007 | 237 | 0.060 |
Why?
|
| Thyroxine-Binding Proteins | 1 | 1986 | 2 | 0.060 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1986 | 25 | 0.060 |
Why?
|
| Prealbumin | 1 | 1986 | 21 | 0.060 |
Why?
|
| Transcriptional Activation | 1 | 2007 | 196 | 0.060 |
Why?
|
| Cryptococcosis | 1 | 2007 | 75 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2007 | 169 | 0.060 |
Why?
|
| Pharmacists | 1 | 2007 | 131 | 0.060 |
Why?
|
| Thyroxine | 1 | 1986 | 55 | 0.060 |
Why?
|
| Ambulatory Care Facilities | 1 | 2006 | 104 | 0.060 |
Why?
|
| Amphotericin B | 1 | 2005 | 21 | 0.060 |
Why?
|
| Respiratory Tract Infections | 1 | 2006 | 90 | 0.060 |
Why?
|
| Intensive Care Units | 2 | 2021 | 435 | 0.060 |
Why?
|
| Medical Errors | 1 | 2007 | 202 | 0.060 |
Why?
|
| Urban Population | 1 | 2006 | 200 | 0.060 |
Why?
|
| Placebos | 1 | 2025 | 73 | 0.060 |
Why?
|
| DNA Helicases | 1 | 2007 | 198 | 0.060 |
Why?
|
| Acetyltransferases | 1 | 2004 | 27 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 857 | 0.050 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2004 | 45 | 0.050 |
Why?
|
| Nerve Growth Factors | 1 | 2004 | 28 | 0.050 |
Why?
|
| Alkynes | 3 | 2015 | 28 | 0.050 |
Why?
|
| Cyclopropanes | 3 | 2015 | 56 | 0.050 |
Why?
|
| Communication | 3 | 2014 | 600 | 0.050 |
Why?
|
| Histoplasma | 1 | 2004 | 16 | 0.050 |
Why?
|
| Massachusetts | 1 | 2010 | 2153 | 0.050 |
Why?
|
| Histoplasmosis | 1 | 2004 | 24 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2003 | 744 | 0.050 |
Why?
|
| Neutropenia | 2 | 1998 | 68 | 0.050 |
Why?
|
| Dideoxynucleosides | 1 | 2003 | 9 | 0.050 |
Why?
|
| Research Design | 2 | 2018 | 590 | 0.050 |
Why?
|
| Interleukin-7 | 1 | 2022 | 29 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2007 | 1659 | 0.050 |
Why?
|
| Interferons | 1 | 2022 | 74 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1231 | 0.050 |
Why?
|
| Linezolid | 1 | 2002 | 7 | 0.040 |
Why?
|
| Influenza A virus | 1 | 2003 | 119 | 0.040 |
Why?
|
| Toxoplasmosis | 1 | 2002 | 21 | 0.040 |
Why?
|
| Osteomyelitis | 1 | 2002 | 24 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2023 | 220 | 0.040 |
Why?
|
| Histones | 1 | 2004 | 495 | 0.040 |
Why?
|
| Survival Rate | 1 | 2003 | 847 | 0.040 |
Why?
|
| Drug Costs | 1 | 2001 | 55 | 0.040 |
Why?
|
| Saquinavir | 1 | 2000 | 1 | 0.040 |
Why?
|
| Megestrol Acetate | 1 | 2000 | 3 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2001 | 165 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2008 | 3155 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 314 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2023 | 753 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 192 | 0.040 |
Why?
|
| Indinavir | 1 | 1999 | 2 | 0.040 |
Why?
|
| Thionucleotides | 1 | 2000 | 39 | 0.040 |
Why?
|
| Ethambutol | 1 | 1999 | 4 | 0.040 |
Why?
|
| Clarithromycin | 1 | 1999 | 6 | 0.040 |
Why?
|
| Antibodies, Protozoan | 1 | 2000 | 56 | 0.040 |
Why?
|
| Ciprofloxacin | 1 | 1999 | 24 | 0.040 |
Why?
|
| Oxazines | 1 | 1999 | 14 | 0.040 |
Why?
|
| Testosterone | 1 | 2000 | 128 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2001 | 318 | 0.040 |
Why?
|
| Lymphoma | 1 | 2000 | 101 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2020 | 278 | 0.040 |
Why?
|
| RNA | 1 | 2023 | 426 | 0.040 |
Why?
|
| Sporotrichosis | 1 | 1999 | 2 | 0.040 |
Why?
|
| Herpesviridae | 1 | 1999 | 15 | 0.040 |
Why?
|
| Cholesterol | 1 | 2000 | 261 | 0.040 |
Why?
|
| Defective Viruses | 1 | 2018 | 4 | 0.040 |
Why?
|
| Disease Reservoirs | 1 | 2018 | 10 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 2776 | 0.040 |
Why?
|
| Skin Tests | 1 | 1998 | 18 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2002 | 641 | 0.030 |
Why?
|
| Immunoblotting | 1 | 1998 | 202 | 0.030 |
Why?
|
| Morbidity | 1 | 1998 | 110 | 0.030 |
Why?
|
| Pneumothorax | 1 | 1998 | 49 | 0.030 |
Why?
|
| Sucralfate | 1 | 1997 | 1 | 0.030 |
Why?
|
| Gastric Acidity Determination | 1 | 1997 | 4 | 0.030 |
Why?
|
| Gastric Acid | 1 | 1997 | 9 | 0.030 |
Why?
|
| Genome, Viral | 1 | 2018 | 144 | 0.030 |
Why?
|
| Ecology | 1 | 1997 | 14 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 1997 | 101 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 1997 | 26 | 0.030 |
Why?
|
| Criminal Law | 1 | 2018 | 87 | 0.030 |
Why?
|
| United States | 3 | 2017 | 8148 | 0.030 |
Why?
|
| Survivors | 1 | 1998 | 187 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1998 | 449 | 0.030 |
Why?
|
| Candida | 2 | 2007 | 37 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2020 | 899 | 0.030 |
Why?
|
| Bacterial Infections | 1 | 1998 | 150 | 0.030 |
Why?
|
| p300-CBP Transcription Factors | 2 | 2007 | 12 | 0.030 |
Why?
|
| Risk | 1 | 1996 | 374 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 1996 | 413 | 0.030 |
Why?
|
| Health Surveys | 1 | 1997 | 317 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 76 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1997 | 465 | 0.030 |
Why?
|
| Femur Head Necrosis | 1 | 1995 | 3 | 0.030 |
Why?
|
| Cefazolin | 1 | 1995 | 8 | 0.030 |
Why?
|
| Switzerland | 1 | 2015 | 17 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2000 | 875 | 0.030 |
Why?
|
| Premedication | 1 | 1995 | 20 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 1995 | 47 | 0.030 |
Why?
|
| Prednisone | 1 | 1995 | 83 | 0.030 |
Why?
|
| Opsonin Proteins | 1 | 2014 | 32 | 0.030 |
Why?
|
| Bacteria, Anaerobic | 1 | 1994 | 5 | 0.030 |
Why?
|
| Blood Bactericidal Activity | 1 | 2014 | 61 | 0.030 |
Why?
|
| Odds Ratio | 1 | 1996 | 755 | 0.030 |
Why?
|
| Clavulanic Acids | 1 | 1994 | 2 | 0.030 |
Why?
|
| Ticarcillin | 1 | 1994 | 3 | 0.030 |
Why?
|
| Genes, Viral | 1 | 1994 | 57 | 0.030 |
Why?
|
| Simplexvirus | 1 | 1994 | 26 | 0.030 |
Why?
|
| Counseling | 1 | 1997 | 376 | 0.030 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2014 | 16 | 0.030 |
Why?
|
| Gentamicins | 1 | 1994 | 24 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2014 | 35 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2014 | 46 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 419 | 0.030 |
Why?
|
| Fever | 1 | 1994 | 65 | 0.030 |
Why?
|
| Antibodies, Bacterial | 1 | 2014 | 181 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2014 | 159 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 1996 | 1114 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 1997 | 425 | 0.020 |
Why?
|
| Biomarkers | 1 | 1999 | 1481 | 0.020 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1994 | 84 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2014 | 257 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1995 | 183 | 0.020 |
Why?
|
| Injections, Intradermal | 1 | 2012 | 12 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 1994 | 513 | 0.020 |
Why?
|
| Immunization, Secondary | 1 | 2012 | 52 | 0.020 |
Why?
|
| Serotyping | 1 | 2012 | 52 | 0.020 |
Why?
|
| Age Factors | 1 | 1996 | 1592 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2014 | 370 | 0.020 |
Why?
|
| Hospitals | 1 | 2015 | 397 | 0.020 |
Why?
|
| Charcoal | 1 | 1991 | 6 | 0.020 |
Why?
|
| Phenytoin | 1 | 1991 | 15 | 0.020 |
Why?
|
| Base Sequence | 1 | 1994 | 1331 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2011 | 48 | 0.020 |
Why?
|
| Animals | 3 | 2011 | 21381 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2011 | 71 | 0.020 |
Why?
|
| Virulence | 1 | 2011 | 199 | 0.020 |
Why?
|
| Hemolysin Proteins | 1 | 2011 | 45 | 0.020 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2010 | 33 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2011 | 261 | 0.020 |
Why?
|
| Liver | 1 | 2014 | 871 | 0.020 |
Why?
|
| Antiprotozoal Agents | 1 | 2009 | 8 | 0.020 |
Why?
|
| Paraplegia | 1 | 2009 | 8 | 0.020 |
Why?
|
| Mandatory Reporting | 1 | 2008 | 16 | 0.020 |
Why?
|
| Ceftriaxone | 1 | 1988 | 20 | 0.020 |
Why?
|
| Myocardium | 1 | 2011 | 302 | 0.020 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2008 | 4 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2010 | 290 | 0.020 |
Why?
|
| Leukemia, Lymphoid | 1 | 1988 | 10 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2010 | 412 | 0.020 |
Why?
|
| North America | 1 | 2008 | 114 | 0.020 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2007 | 9 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 158 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2009 | 210 | 0.020 |
Why?
|
| Europe | 1 | 2008 | 199 | 0.020 |
Why?
|
| Trimethoprim | 1 | 2007 | 7 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 1988 | 254 | 0.020 |
Why?
|
| Azoles | 1 | 2007 | 1 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 297 | 0.020 |
Why?
|
| Werner Syndrome Helicase | 1 | 2007 | 2 | 0.020 |
Why?
|
| Werner Syndrome | 1 | 2007 | 3 | 0.020 |
Why?
|
| Gallium | 1 | 2007 | 12 | 0.020 |
Why?
|
| Citrates | 1 | 2007 | 19 | 0.020 |
Why?
|
| Inpatients | 1 | 2010 | 322 | 0.020 |
Why?
|
| Doxycycline | 1 | 2007 | 47 | 0.020 |
Why?
|
| Exodeoxyribonucleases | 1 | 2007 | 29 | 0.020 |
Why?
|
| Enzymes | 1 | 2007 | 35 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1986 | 63 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 196 | 0.010 |
Why?
|
| Respiratory Insufficiency | 1 | 2008 | 154 | 0.010 |
Why?
|
| Outpatients | 1 | 2007 | 143 | 0.010 |
Why?
|
| Vomiting | 1 | 2007 | 139 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2010 | 452 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2007 | 209 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2007 | 541 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2011 | 741 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1988 | 506 | 0.010 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 2004 | 13 | 0.010 |
Why?
|
| PC12 Cells | 1 | 2004 | 27 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2011 | 924 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2007 | 422 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 796 | 0.010 |
Why?
|
| Acetylation | 1 | 2004 | 121 | 0.010 |
Why?
|
| Pheochromocytoma | 1 | 2004 | 31 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 2004 | 54 | 0.010 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2004 | 83 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2004 | 240 | 0.010 |
Why?
|
| Cell Line | 1 | 1988 | 2024 | 0.010 |
Why?
|
| Drug Eruptions | 1 | 2003 | 17 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 2305 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 501 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 700 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 2111 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2003 | 69 | 0.010 |
Why?
|
| Mortality | 1 | 2003 | 162 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 1588 | 0.010 |
Why?
|
| Cough | 1 | 2003 | 183 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 1996 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 1567 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2008 | 1161 | 0.010 |
Why?
|
| Lamivudine | 1 | 1999 | 7 | 0.010 |
Why?
|
| Zidovudine | 1 | 1999 | 12 | 0.010 |
Why?
|
| Logistic Models | 1 | 2003 | 1273 | 0.010 |
Why?
|
| Sporothrix | 1 | 1999 | 3 | 0.010 |
Why?
|
| Antitubercular Agents | 1 | 1999 | 84 | 0.010 |
Why?
|
| Mice | 1 | 2011 | 11138 | 0.010 |
Why?
|
| Patient Care Team | 1 | 1999 | 336 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1999 | 1284 | 0.010 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 1991 | 19 | 0.010 |
Why?
|
| Poisoning | 1 | 1991 | 27 | 0.010 |
Why?
|
| Liver Diseases | 1 | 1991 | 157 | 0.000 |
Why?
|